Literature DB >> 25260306

Hepatocellular carcinoma epidemiology.

Cristina Bosetti1, Federica Turati2, Carlo La Vecchia3.   

Abstract

Primary liver cancer (namely hepatocellular carcinoma, HCC) is worldwide the fifth most common cancer in men and the seventh one in women, and it represents the third most frequent cause of cancer death. HCC rates are particularly high in eastern/south-eastern Asia and in Africa, intermediate in Southern Europe, and low in most high-income countries. Persistent infections by HBV or HCV are the main recognized risk factors for HCC. Aflatoxin exposure is also an important risk factor for HCC development in Africa and eastern Asia. In high-income countries heavy alcohol drinking, tobacco smoking, overweight, diabetes, familial/genetic factors, and selected dietary aspects, have a relevant role. Updated geographic patterns and time trends in mortality from HCC in Europe, USA, Japan, and Australia are provided in the present review, together with an overview of relevant etiologic factors for HCC and main measures for the prevention of this neoplasm.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Hepatitis virus; Hepatocellular cancer; Liver cancer; Risk factors

Mesh:

Year:  2014        PMID: 25260306     DOI: 10.1016/j.bpg.2014.08.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  198 in total

1.  Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.

Authors:  Manal M Hassan; Reham Abdel-Wahab; Ahmed Kaseb; Ahmed Shalaby; Alexandria T Phan; Hashem B El-Serag; Ernest Hawk; Jeff Morris; Kanwal Pratap Singh Raghav; Ju-Seog Lee; Jean-Nicolas Vauthey; Gehan Bortus; Harrys A Torres; Christopher I Amos; Robert A Wolff; Donghui Li
Journal:  Gastroenterology       Date:  2015-03-30       Impact factor: 22.682

Review 2.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

3.  MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6.

Authors:  Cheng-Jun Sui; Feng Xu; Wei-Feng Shen; Bing-Hua Dai; Jiong-Jiong Lu; Min-Feng Zhang; Jia-Mei Yang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

4.  Multi-omics in prognosis of hepatocellular carcinoma.

Authors:  Anna Lena Ress; Rishi Wagle; Martin Pichler
Journal:  Ann Transl Med       Date:  2015-01

5.  Green tea and liver cancer.

Authors:  Francesca Bravi; Carlo La Vecchia; Federica Turati
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 6.  Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.

Authors:  Shirin Elizabeth Khorsandi; Nigel Heaton
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-06

Review 7.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

8.  High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients.

Authors:  Yongqing Xu; Xianmin Bu; Chaoliu Dai; Chao Shang
Journal:  Tumour Biol       Date:  2015-02-01

Review 9.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

10.  Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.

Authors:  Hao Wu; Yan Liu; Xiao-Wei Jiang; Wen-Fang Li; Gang Guo; Jian-Ping Gong; Xiong Ding
Journal:  Tumour Biol       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.